Personalized Biomarker-Guided Treatment for Women with Endometrial and Ovarian Cancer Using Hormone Receptors and Stathmin Levels
Led by Haukeland University Hospital · Updated on 2017-03-28
1300
Participants Needed
9
Research Sites
678 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of specific molecular biomarkers to personalize treatment for patients with endometrial cancer. This study focuses mainly on biomarkers found promising in previous research and aims to improve surgical and medical treatment decisions. The trial has two parts one tests the use of biomarkers to guide lymphadenectomy during surgery, and the other assesses the biomarker stathmins potential to predict response to taxane chemotherapy in endometrial and ovarian cancer.
The study includes an implementation phase where lymphadenectomy is performed based on hormone receptor status ER and PR to define patient risk and guide surgery. Patients considered low risk based on tumor grade and receptor status may avoid lymphadenectomy, while higher-risk patients undergo pelvic and para-aortic lymphadenectomy. In the second phase, patients receiving weekly taxane treatment have tissue biopsies and urine samples analyzed for stathmin levels before and during treatment. Imaging scans and blood tests are conducted regularly to monitor disease progression.
Participants will receive routine clinical follow-up for five years, including quality of life questionnaires. Researchers will collect data on survival, disease recurrence, and quality of life over this period. For patients in the taxane treatment phase, urine and blood samples will be collected weekly, with imaging every eight treatment cycles. The studys main outcomes include the number of cancer recurrences after five years and the duration of treatment response in metastatic disease, along with correlations of stathmin levels in various samples.
CONDITIONS
Brief Title
Biomarker Guided Treatment in Gynaecological Cancer
Research Team
J
Jone Trovik, MD PhD Prof
H
Henrica MJ Werner, MD PhD MRCOG
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients referred with suspicion of or confirmed endometrial cancer
Female patients aged 18 to 95 years
Patients with endometrial or epithelial ovarian cancer offered weekly taxane treatment
Ability to obtain a new tissue biopsy for stathmin level analysis
Ability to provide informed consent
You will not qualify if you...
Patients without endometrial or epithelial ovarian cancer
Patients under 18 years of age
Patients unable or unwilling to give informed consent, including language barriers
Patients who will not receive surgical treatment for endometrial cancer
Patients who decline or cannot receive proposed treatment at participating centers
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery
Duration - Surgical procedure day
Participants undergo surgery with lymphadenectomy decisions guided by their biomarker (ER/PR) status. Low risk patients avoid lymphadenectomy while high risk patients receive pelvic and para-aortic lymphadenectomy as part of their surgical procedure.
1 surgical visit (in-person)
Treatment
Duration - Weekly cycles until disease progression
Participants receive weekly taxane treatment guided by biomarker stathmin levels, with urine and blood collected every treatment cycle and imaging every 8 cycles. Treatment continues until disease progression.
Weekly visits for treatment and assessments
Follow-up
Duration - 5 years
Participants are followed with routine clinical visits for 5 years to monitor survival and recurrence, and to complete quality of life questionnaires.
Regular follow-up visits over 5 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase III Trial Comparing BNT323 Versus Chemotherapy for HER2-Positive Recurrent Endometrial Cancer
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study of CTIM-76, a Claudin-6 Directed Bispecific Antibody, in Adults With Platinum-Resistant Ovarian Cancer and Advanced Solid Tumors
Phase 1 Open-label Study of LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, Given Intravenously in Advanced Solid Tumors to Determine Safety and Recommended Dose
Phase 1a1b Study of NRM-823 Alone and With Immune Checkpoint Inhibitor in Advanced or Metastatic Refractory Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study.
David Forsse, Mark L Barbero, Henrica M J Werner...